How it works:
Linagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It blocks the enzyme responsible for degrading incretin hormones (GLP-1 and GIP), which enhance glucose-dependent insulin secretion and suppress glucagon release. This mechanism lowers blood glucose levels with a low risk of hypoglycemia when used alone. The medication provides 24-hour activity, allowing once-daily dosing.
Who it is recommended for:
Clinical studies and evidence:
Linagliptin has been evaluated in large international clinical trials demonstrating significant reductions in HbA1c levels. Studies confirm sustained glycemic control and a favorable safety profile. The drug is weight-neutral and associated with a low risk of hypoglycemia when not combined with insulin secretagogues. Long-term trials have also demonstrated cardiovascular safety.
Indicated for the treatment of type 2 diabetes mellitus in adults. Used to improve blood glucose control in combination with diet and exercise. It works by enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.
Take orally once daily, with or without food. The tablet should be swallowed whole with water. Duration of therapy depends on individual glycemic response and physician assessment.
Contraindications
Side effects
